{"abstract": "The $1.75 billion deal for Alios BioPharma, which is working on treatments for viral diseases, is the first acquisition in some time for Johnson & Johnson.", "web_url": "https://dealbook.nytimes.com/2014/09/30/johnson-johnson-to-buy-biotech-company-alios/", "snippet": "The $1.75 billion deal for Alios BioPharma, which is working on treatments for viral diseases, is the first acquisition in some time for Johnson & Johnson.", "lead_paragraph": "Johnson & Johnson said on Tuesday that it would pay $1.75 billion in cash for Alios BioPharma, a private biotechnology company that is working on treatments for viral diseases. ", "print_section": "B", "print_page": "4", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/01/business/dbpix-johnson/dbpix-johnson-articleLarge.jpg", "height": 403, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/10/01/business/dbpix-johnson/dbpix-johnson-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 403}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/01/business/dbpix-johnson/dbpix-johnson-jumbo.jpg", "height": 687, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/01/business/dbpix-johnson/dbpix-johnson-superJumbo.jpg", "height": 1374, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/01/business/dbpix-johnson/dbpix-johnson-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/10/01/business/dbpix-johnson/dbpix-johnson-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/01/business/dbpix-johnson/dbpix-johnson-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Johnson & Johnson to Buy Biotech Company Alios BioPharma", "kicker": "DealBook", "content_kicker": null, "print_headline": "Change of Focus", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Biotechnology", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 3, "major": "N"}, {"name": "subject", "value": "Respiratory Syncytial Virus (RSV)", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Janssen Pharmaceutica", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Johnson & Johnson", "rank": 6, "major": "N"}], "pub_date": "2014-09-30T14:10:05+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By David Gelles", "person": [{"firstname": "David", "middlename": null, "lastname": "Gelles", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/875458fa-1252-59cc-9cab-e141c8007049", "word_count": 407, "uri": "nyt://article/875458fa-1252-59cc-9cab-e141c8007049"}